FDA issued Emergency Use Authorization of Convalescent Plasma for COVID-19 treatment
The U.S. Food and Drug Administration has issued Emergency Use Authorisation (EUA) for convalescent plasma for treating patients with COVID-19. The drug can be administered for hospitalized patients, and the FDA has announced that the approval is based on the available scientific evidence. FDA announced that plasma treatment has benefits, and benefits outweigh the risks.
FDA has announced that it has reviewed the scientific data generated over the months since the outbreak of the pandemic. The organization has announced that more than 70,000 patients treated with plasma were recovered from the pandemic.
The plasma is taken from the patients who were recovered from the infection. At the end of March, the FDA has set up a team of scientists to analyze the use of plasma for treating the infection with plasma.
As per the directions provided by the FDA, patients can accept or refuse the plasma treatment. It is mandatory for the healthcare providers to provide the Fact Sheet to the patients with the necessary information on known potential risks and benefits.
“The FDA’s emergency authorization for convalescent plasma is a milestone achievement in President Trump’s efforts to save lives from COVID-19,” said Secretary Azar.
The plasma will be administered by the healthcare providers as the standard hospital procedures.
For pipeline, market overview, SLRs, and market access reports (syndicate and customised) please write to email@example.com
For all syndicate reports: Click here